Supplementary Information

Methods

Cell culture infection assay

VeroE6/TMPRSS2 cells, a VeroE6 cell clone overexpressing the transmembrane protease, serine 2 (TMPRSS2), were cultured in Dulbecco's modified Eagle's medium (Life Technologies) supplemented with 10% fetal bovine serum (FBS) (Sigma), 100 units/mL penicillin, 100 μ g/mL streptomycin, 10 mM HEPES (pH 7.4), and 1 mg/mL G418 (Nacalai) at 37°C in 5% CO2 (Ohashi et al., 2021).

SARS-CoV-2 was investigated in a biosafety level 3 (BSL3) room. Through viral inoculation, we used WK-521 (Wuhan strain, EPI_ISL_408667), QK002 (Alpha, EPI_ISL_768526), TY7-501 (Gamma, EPI_ISL_833366), TY11-927 (Delta, EPI_ISL_2158617), TY38-873 (Omicron BA.1, EPI_ISL_7418017), and TY40-385 (Omicron BA.2, EPI_ISL_9595859) strains, isolated from COVID-19 patients and registered in GISAID. Viral infectious titers were measured by inoculating VeroE6/TMPRSS2 cells with a 10-fold serial dilution of the virus followed by measuring cytopathology to calculate TCID₅₀/ml (Ohashi et al., 2021). Infection assay was conducted by inoculating VeroE6/TMPRSS2 cells with each SARS-CoV-2 strain at an MOI of 0.003 for 1 h, followed by washing out free viruses and culturing cells with fresh medium. A medium with 2% FBS without G418 was used during the infection assay. Antibodies and antiviral drugs were treated for 1 h during virus inoculation and 24 h after inoculation. At 24 h postinfection, the culture supernatant was recovered to isolate RNA using MagMax Viral/Pathogen Nucleic Acid Isolation kit (Thermo Fisher Scientific) and quantify SARS-CoV-2 RNA by real time RT-PCR with a one-step qRT-PCR kit (THUNDERBIRD Probe One-step qRT-PCR 5'-ACAGGTACGTTAATAGTTAATAGCGT-3', kit, TOYOBO) 5'using ATATTGCAGCAGTACGCACACA-3', and 5'-FAM-ACACTAGCCATCCTTACTGCGCTTCG-TAMRA-3'. Simultaneously, cell viability was quantified by fixing the cells with 4% paraformaldehyde and staining with DAPI to count the number of cells using a high content imaging system ImageXpress (Molecular Devices).

Statistics

Statistical significance was determined by using Student's t test. P-values < 0.05 were considered significant. Where applicable, P-values are indicated as *P < 0.05 or **P < 0.01.

Supplementary Figure

Fig. S1




Fig. S1. Cell viability upon treatment with neutralizing antibodies and antiviral drugs. VeroE6/TMPRSS2 cells were inoculated with SARS-CoV-2 at an MOI of 0.003 in the presence of indicated antibodies or drugs at indicated concentrations for 1 h. The cells were then washed out and were cultured in a medium supplemented with the indicated concentrations of antibodies or drugs. After 24 h, cells were subsequently fixed with 4% paraformaldehyde and stained with DAPI, followed by counting using a high content imaging system ImageXpress Micro Confocal (Molecular Devices) to quantify cell viability. Data are presented as mean \pm SD across the three replicate experiments. Relative values are shown as percentages of cell viability to the control cells that were incubated without antibodies/drugs. Statistical significance was determined by using Student's t test (*p <0.05, **p <0.01).






Figure. S2. Dose-response curves of casirivimab for SARS-CoV-2 variants (Wuhan, alpha, gamma, delta, omicron BA.1, and omicron BA.2). Secreted viral RNA into the supernatant from infected VeroE6/TMPRSS2 cells at 24 hours after virus inoculation was quantified and plotted in gray against drug concentration. Values less than 0.1% are shown as 0.1% in these graphs.



imdevimab




Figure. S3. Dose-response curves of imdevimab for SARS-CoV-2 variants (Wuhan, alpha, gamma, delta, omicron BA.1, and omicron BA.2). Secreted viral RNA into the supernatant from infected VeroE6/TMPRSS2 cells at 24 hours after virus inoculation was quantified and plotted in gray against drug concentration. Values less than 0.1% are shown as 0.1% in these graphs.

Fig. S4 S309




Figure. S4. Dose-response curves of S309 for SARS-CoV-2 variants (Wuhan, alpha, gamma, delta, omicron BA.1, and omicron BA.2). Secreted viral RNA into the supernatant from infected VeroE6/TMPRSS2 cells at 24 hours after virus inoculation was quantified and plotted in gray against drug concentration. Values less than 0.1% are shown as 0.1% in these graphs.

Fig. S5 EIDD-1931




Figure. S5. Dose-response curves of EIDD-1931 for SARS-CoV-2 variants (Wuhan, alpha, gamma, delta, omicron BA.1, and omicron BA.2). Secreted viral RNA into the supernatant from infected VeroE6/TMPRSS2 cells at 24 hours after virus inoculation was quantified and plotted in gray against drug concentration. Values less than 0.1% are shown as 0.1% in these graphs.






Figure. S6. Dose-response curves of nirmatrelvir for SARS-CoV-2 variants (Wuhan, alpha, gamma, delta, omicron BA.1, and omicron BA.2). Secreted viral RNA into the supernatant from infected VeroE6/TMPRSS2 cells at 24 hours after virus inoculation was quantified and plotted in gray against drug concentration. Values less than 0.1% are shown as 0.1% in these graphs.

Supplementary Table

Drug	C _{max} (unit)	AUC (unit)	Molecular mass (unit)
casirivimab	192 (µg/mL)	2580 (day*µg/mL)*1	145230 (g/mol)
imdevimab	198 (µg/mL)	1990 (day*µg/mL)*1	144140 (g/mol)
S309	143 (µg/mL)	1410 (day*µg/mL)*²	149000 (g/mol)
EIDD-1931	2.97 (µg/mL)	602.0 (day*µM)*3	329.31 (g/mol)
nirmatrelvir	2.21 (µg/mL)	1105 (day*µM) ^{*4}	499.54 (g/mol)

Table. S1. Drug concentrations in patients

^{*1} AUC_{inf}, 600 mg subcutaneous injection

^{*2} AUC_{D1-29}, sotrovimab 500 mg intravenous infusion

^{*3} AUC_{0-12h}, 800 mg oral administration in patients

^{*4} AUC_{inf}, 300 mg with ritonavir (100 mg) oral administration in healthy subjects

The pharmacokinetics of these antibodies/drugs are available in reference articles (2-5).

References

1. Ohashi, H., Watashi, K., Saso, W., Shionoya, K., Iwanami, S., Hirokawa, T., Shirai, T., Kanaya, S., Ito, Y., Kim, K.S., et al. (2021). Potential anti-COVID-19 agents, cepharanthine and nelfinavir, and their usage for combination treatment. iScience 24, 102367. doi: 10.1016/j.isci.2021.102367

2. Food and Drug Administration (2021) Fact Sheet for Health Care Providers Emergency Use Authorization (EUA) of REGEN-COV (casirivimab and imdevimab). https://www.fda.gov/media/145611/download

3. Food and Drug Administration (2022) Fact Sheet for Health Care Providers Emergency Use Authorization (EUA) of Sotrovimab. https://www.fda.gov/media/149534/download

4. Food and Drug Administration (2022) Fact Sheet for Health Care Providers Emergency Use Authorization (EUA) of Molnupiravir. https://www.fda.gov/media/155054/download

5. Food and Drug Administration (2021) Fact Sheet for Health Care Providers Emergency Use Authorization (EUA) of Paxlovid. https://www.fda.gov/media/155050/download